At IDWeek 2025, held in Atlanta, Georgia, USA, from October 19-22, 2025, Dr. Nguyen Hoa Anh representing LiveSpo Pharma and Assoc. Prof. Dr. Nguyen Thi Van Anh representing the Spobiotic Research Center – ANABIO R&D, presented new research findings on the effectiveness of nasal-spray Bacillus spores in preventing respiratory infections in children. This study is part of a collaborative effort among the Institute for Preventive Medicine and Public Health – Hanoi Medical University, Hanoi University of Public Health, and several other research institutions.
The conference brought together more than 10,000 physicians and scientists from over 100 countries and is recognized as one of the world’s leading forums in infectious diseases and antimicrobial resistance. IDWeek features a wide range of cutting-edge scientific updates through plenary sessions, keynote lectures, pre-meeting workshops, symposia, oral presentations, and poster sessions across specialized tracks such as antimicrobial resistance and stewardship, HIV, pediatric infectious diseases, public health, respiratory, gastrointestinal, urinary and sexually transmitted infections, epidemiology, and community healthcare.
The team’s poster booth attracted strong interest from many infectious disease physicians, hospital-based laboratory researchers, and R&D specialists from numerous countries, including the United States, the United Kingdom, Switzerland, France, Sweden, Spain, Colombia, Canada, Japan, Brazil, China, India, and Tanzania.
Throughout the exhibition, the team engaged in scientific discussions with visitors on topics related to LiveSpo Navax-the nasal-spray Bacillus spore probiotic for preventing and supporting the treatment of respiratory infections. Key discussion themes included product composition and mechanisms of action, modulation of the nasal microbiome, and its role in preventing and alleviating respiratory infections.
Many scientists expressed particular interest in the concept of a “nasal-spray probiotic,” viewing it as an innovative direction in microbial technology for respiratory health protection. They highly appreciated the product’s safety profile-showing no mucosal irritation and no adverse effects reported during clinical trials. Several researchers were especially intrigued by the adhesion and activity of Bacillus spores on the nasal mucosa, their potential to protect against multiple respiratory viruses, and the prospect of expanding research into other population groups beyond children.
Participating in IDWeek 2025 provided an important opportunity for ANABIO R&D’s Spobiotic Research Center to present Vietnam’s scientific achievements to the international community, while expanding collaborations in probiotics and in the biological, safe control of infectious diseases.
